Form 4: Enliven Therapeutics CEO Samuel Kintz Sells 12,000 Shares
SEC Form 4 Filing
Enliven Therapeutics CEO Samuel Kintz sold 12,000 shares of common stock on August 26, 2024, at a weighted average price of $22.8932 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 26, 2024, Samuel Kintz, the President and CEO of Enliven Therapeutics, sold 12,000 shares of the company's common stock.
- The sale was executed at a weighted average price of $22.8932 per share, with individual transaction prices ranging from $22.60 to $23.26.
- The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following the transaction, Kintz directly owns no shares, but indirectly owns 1,049,255 shares through The Kintz & Egan Trust Dated March 30, 2019, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a routine stock sale by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing indicates insider trading activity, which is common for executives. The sale was conducted under a pre-arranged 10b5-1 trading plan, which is a legal way for insiders to sell shares without being accused of trading on non-public information.
Stakeholder Impact
- The sale of shares by the CEO could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| March 30, 2019 | Date of The Kintz & Egan Trust |
| June 26, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| August 26, 2024 | Date of stock sale |
| August 28, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.